Tubulis GmbH secured an oversubscribed €308 million (about $356 million) Series C—the largest private ADC‑focused Series C in Europe—to accelerate clinical development of its lead ADC TUB‑040 and to expand indications. The company plans to use the funding to validate clinical signals and push programs into later lines and earlier settings. Tubulis designs and optimizes all ADC elements in‑house, a strategy investors backed to improve payload delivery and antibody properties. The round signals sustained investor appetite for differentiated ADC platforms despite crowded oncology markets.